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The epidermal growth factor receptor (EGFR) is expressed in a wide variety of epithelial tumours including carcinoma of the bladder.
Stimulation of the EGFR pathway is blocked by ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor. Radical
radiotherapy is an established organ sparing treatment option for muscle invasive bladder cancer and this study has explored the
possibility for the use of ZD1839 as a radiosensitiser in this scenario. The effect of combination treatment with ZD1839 (0.01mM)
and ionising radiation in the established bladder cancer cell lines MGH-U1 and its radiosensitive mutant clone S40b was measured by
clonogenic assays. A highly significant radiosensitising effect was seen in both cell lines (Po0.001 for MGH-U1 and S40b cell lines).
This effect was independent of the concentration of the drug and the duration of exposure prior to treatment with ionising radiation.
Cell cycle kinetics of both cell lines was not significantly altered with ZD1839 (0.01mM) as a single agent. A modest induction of
apoptosis was observed with ZD1839 (0.01mM) as a single agent, but a marked induction was observed with the combination
treatment of ZD1839 and ionising radiation. These results suggest a potentially important role for ZD1839 in combination with
radiotherapy in the treatment of muscle invasive bladder cancer.
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Carcinoma of the bladder is the second most common malignancy
of the genitourinary tract accounting for 13600 new cases in the
UK in 1999 (Quinn et al, 1999) and an estimated 132000
directly related deaths worldwide in 2000 (Ferlay et al,
2000). Radical radiotherapy is an established organ preserving
treatment option for muscle invasive disease with an overall 5-year
survival comparable to that of radical surgery in some cases
(Shelley et al, 2001). There are continuing improvements in the
accuracy of delivered radiotherapeutic dose and reductions of
target volume irradiated (Zelefsky et al, 1998). The use of
radiosensitising agents has also been explored in an attempt to
improve efficacy and minimise toxicity (Hennequin and Favaudon,
2002).
The epidermal growth factor receptor (EGFR) is one of a family
of four closely related transmembrane glycoprotein receptors
consisting of an extracellular ligand binding domain, a transmem-
brane domain and an intracellular tyrosine kinase domain. The
receptor exists as an inactive monomer that undergoes homo- or
heterodimerisation after activation by ligands such as epidermal
growth factor (EGF) and transforming growth factor-a (TGF-a).
This results in receptor-associated tyrosine kinase activation,
which triggers a cascade of downstream signalling pathways
resulting in cell cycle progression, proliferation, angiogenesis and
cell survival. A wide variety of human tumours including breast,
NSCLC, bladder and SCC of the head and neck have been reported
as expressing moderate to high levels of EGFR (Salomon et al,
1995). Activation of EGFR has been shown to result in accelerated
tumour growth and is associated with a poor patient prognosis in
many solid tumours (Nicholson et al, 2001). It has been suggested
that cell survival and repopulation may be enhanced by activation
and expression of EGFR and the ligand TGF-p that is induced
following irradiation (Schmidt-Ullrich et al, 1994, 1996, 1997). In
view of the crucial importance of the EGFR-mediated signalling
cascade to cancer therapeutics, this receptor has been the focus of
intense research.
ZD1839, a synthetic anilinoquinazoline, is an orally active,
highly selective EGFR tyrosine kinase inhibitor (EGFR-TKI) that
inhibits ligand-stimulated EGFR autophosphorylation and signal
transduction pathways implicated in the promotion of cancer cell
growth and proliferation (Woodburn, 1999). Treatment of the
EGFR signalling cascade with ZD1839 offers the potential
to modulate and inhibit the inbuilt pathways that protect
against ionising radiation and therefore improve the efficacy of
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sradiation-induced cell death (Ciardiello and Tortora, 2001b). In
this study, we examined whether combination treatment with
ZD1839 and ionising radiation resulted in increased cell death in
two closely related bladder cancer cell lines MGH-U1 and its
relatively radiosensitive derivative, S40b (McMillan and Holmes,
1991). The effects of combination treatments on cell cycle
kinetics and apoptosis were also investigated.
MATERIALS AND METHODS
Chemicals and cell lines
The established human bladder cancer cell line MGH-U1 and its
radiosensitive mutant clone S40b were cultured in Hams F12
media with 10% foetal calf serum, 1% glutamine and 1% penicillin
and streptomycin. Both cell lines were kindly donated by Professor
T McMillan (Lancaster, UK) and Dr S Powell (Boston, USA).
ZD1839 (Iressa) was kindly donated by Astra Zeneca Pharmaceu-
ticals (Macclesfield, UK).
Clonogenic assays with ZD1839
Exponentially growing cells from both cell lines were treated with
ZD1839 at final concentrations ranging from 0.01 to 10mM for 24h.
The drug was removed by washing twice with PBS. The cells were
then trypsinised, counted using a Coulter Multisizer II Cell
Counter
s and plated into 60mm dishes with 5ml of media. The
dishes were incubated for 10 days at 371C and 5% CO2. The media
were aspirated and the plates were stained with 1% crystal violet
and surviving colonies with greater than 50 cells per colony were
counted.
Growth inhibition assay
Exponentially growing cells were treated continuously for 6 days
with 10ml of ZD1839 at final concentrations ranging from 0.01 to
1000mM. The drug was changed every 24h and a further 10ml of
freshly reconstituted ZD1839 was added. On day 7, the cells were
trypsinised and counted using a Coulter Multisizer II Cell
Counter
s.
Clonogenic assay with ZD1839 and irradiation
Exponentially growing cells were treated with single doses of
radiation (0–10Gy) in a sealed Caesium-137 gamma-irradiator.
The irradiated cells were trypsinised, counted using a Coulter
Multisizer II Cell Counter
s and plated in 60mm Petri dishes
and incubated as before. The process was repeated for exponen-
tially growing cells treated with ZD1839 at concentrations
ranging from 0.01 to 10mM for 1–6 days prior to irradiation.
The drug was replenished daily. Colonies were stained and counted
as before. The clonogenic survival data were fitted to a radiation
survival curve using the using the linear quadratic equation
and the DRFIT Radiation Survival Fitting Program (Roberts,
1990). Differences were assessed using analysis of variance and an
F-test.
EGFR expression
The expression of EGFR was determined using an EGFR Elisa
Analysis Kit (Oncogene Research Products, San Diego). Exponen-
tially growing cells were treated with a detector antibody to EGFR
and incubated at 371C for 4h. After washing with buffer supplied
with the kit, horseradish peroxidase-conjugated streptavidin was
added and after 1h absorbance was measured using a Plate Reader
at 450/595nm.
Cell cycle analysis
Cell cycle distribution was analysed at 0, 24 and 48h after exposure
to ZD1839 for 24h using flow cytometry with propidium iodide
(PI) staining. Cells were treated with ZD1839 (0.01–10mM) for
24h. The drug was washed off with media twice. For cell cycle
distribution analysis at 0h following exposure to ZD1839 for 24h,
cells were treated as described below. For cell cycle distribution
analysis at 24 and 48h following exposure to ZD1839, 10ml of
media was added and cells were incubated at 371C for a further 24
and 48h from the time of exposure to ZD1839. The cells were
trypsinised, centrifuged at 1000r.p.m. for 5min, then washed with
PBS and centrifuged at 2000r.p.m. for 5min. Cell pellets were fixed
with 500ml of ice-cold 70% ethanol and quickly vortexed. The cells
were centrifuged at 2000r.p.m. and the supernatant discarded.
Ribonuclease A (50ml of 100mlml
 1 solution) was added and
incubated for 5min. PI stain (300mlo f5 0 mgml
 1 solution) was
added and incubated for 15min. The specimens were analysed
using Flow Cytometry at 620nm.
Apoptosis analysis
Apoptosis was evaluated using Annexin V–FITC conjugates and PI
staining. Exponentially growing cells were treated with ZD1839
(0.01mM) for 24h followed by irradiation (2–10Gy), or received
irradiation alone (2–10Gy). The cells were trypsinised and
centrifuged at 1000r.p.m. for 5min. The pellets were washed with
500ml of cold PBS, centrifuged at 500g for 5min and 1ml of
binding buffer was added per 10
6 cells. A measure of 10mlo f
25mgml
 1 Annexin V–FITC and PI stain (10mlo f5 0 mgml
 1
solution) were added and samples were incubated in the dark for
15min. The samples were analysed using flow cytometry.
RESULTS
Growth inhibition and clonogenic survival
‘The clonogenic survival of both cell lines was not significantly
affected by exposure to ZD1839 for 24h, compared to that of the
controls, at the concentrations studied (0.01–10mM). The length of
continuous exposure to ZD1839 (1–6 days) at concentrations of 0.01–
10mM also had no significant effect on cell counts or on clonogenic
survival after 10 days (six doubling times) (data not shown).
Continuous exposure to ZD1839 at concentrations up to 1000mM
for 6 days with the drug being replenished every 24h resulted in a
significant growth inhibitory effect at high concentrations of the
drug. The IC50 calculated on cell counts was 98 and 59mM,

























Figure 1 Survival of cells treated with ZD1839 (0.01–1000mM) for 6
days with drug replenished daily. Cell counts were performed after day 6 of
drug exposure. The IC50 was 59mM for S40b and 98mM for MGH-U1,
respectively.
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sZD 1839 and irradiation
ZD1839 demonstrated a significant radiosensitising effect on both
the radiosensitive S40b cell line (Po0.001) and the radioresistant
MGH-U1 cell line (Po0.001). For MGH-U1, the survival fraction at
2Gy (SF2) was 0.88 and at 10Gy (SF10) was 0.042. For S40b, the SF2
was 0.66 and the SF10 was 0.0079. The SF2 for the combination
exposure to ZD1839 for 24h preirradiation at a concentration of
0.01mM was 0.83 and 0.42 for MGH-U1 and S40b, respectively. The
SF10 for the combination exposure to ZD1839 for 24h preirradia-
tion at a concentration of 0.01mM was 0.012 and 0.00146 for MGH-
U1 and S40b respectively, Figure 2. The radiosensitising effect of
ZD1839 on cell kill was found to be more pronounced at higher
radiation doses as demonstrated by the SF10 values. Prolonged
exposure to ZD1839 for 3 and 6 days preirradiation with the drug
being replenished daily did not improve the overall radiosensitis-
ing effect of the 24h exposure regimen. In the MGH-U1 cell line,
the SF2 for 3 and 6 days exposure was 0.80 and 0.83 and the SF10
was 0.0089 and 0.0109, respectively. In the S40b cell line, the SF2
for 3 and 6 days exposure was 0.43 and 0.456 and the SF10 was
0.00238 and 0.00165, respectively, Figure 3. Thus, the radio-
sensitising effect was demonstrated to be independent of the length
of exposure preirradiation in both the MGHU-1 and the S40b cell
lines, with exposure for 24h having the same effect as continuous
exposure for 6 days preirradiation. The radiosensitising effect was
found to be independent of the dose of ZD1839 at the
concentrations studied, with exposure to 10 and 0.01mM having
no statistically significant difference in both cell lines (P¼0.8 and
0.84 in MGH-U1 and S40b), Figure 4.
Both cell lines demonstrated a moderate expression of EGFR,
with the radiosensitive S40b cell line expressing higher levels
(21.5fmmg
 1 of protein) than the radioresistant MGH-U1 cell line
(16.7fmmg
 1 of protein).
Effects of ZD1839 on cell cycle
Analysis of cell cycle kinetics at 0, 24 and 48h postexposure to
ZD1839 (0.1 and 10mM) revealed no demonstrable alteration in the
proportion of cells in different phases of the cell cycle in relation to
control cells. There was no significant accumulation of cells in the
G0/G1 phase of the cell cycle in the MGH-U1 cell line (70.3% in the
control sample vs 68.8 and 65.7% in the 0.1 and 10mM samples,
respectively), or in the S40b cell line (45.5% in the control sample
vs 49.9 and 51.7% in the 0.1 and 10mM samples, respectively).
Similarly, there was no significant alteration in the proportion of
cells in the S phase of the cell cycle in either cell line at either
concentration of ZD1839 (15.2% in the control sample vs 16.2 and
16.6% in the 0.1 and 10mM samples in the MGH-U1 cell line and 28
vs 27.7 and 21.9% in the 0.1 and 10mM samples in the S40b cell
line), Figure 5.
Effect of ZD1839 on apoptosis
ZD1839 was found to have a modest proapoptotic effect on both
cell lines as a single agent resulting in the induction of apoptosis in
the MGH-U1 cell line (11.1% compared to control values of 5.3%).
A similar effect on the S40b cell line was also noted (10.8%
compared to control values of 5.7%). Treatment of both cell lines
with radiation alone resulted in the induction of apoptosis in both
cell lines with a greater proportionate induction in the S40b
radiosensitive cell line (12.5 vs 5.3% in control samples for MGH-
U1 cells and 17.8 vs 5.7% in the control sample for S40b cells).
Following the combination of ZD1839 and radiation, there was a
significant induction of apoptosis in both the radiosensitive and




















































Figure 2 Radiosensitising effect of exposure to ZD1839 for 24h prior to
treatment with ionising radiation. Radiation Survival curves were plotted for
the MGH-U1 cell line (K) and the S40b cell line (m) without ZD1839.
Radiation survival curves were plotted for both cell lines following
treatment with ZD1839 (0.01mM) for 24h prior to irradiation. A highly
significant radiosensitising effect was demonstrated for both cell lines
treated with ZD1839 over the radiation dose range examined (Po0.001







































































































Figure 3 Radiosensitising effect of exposure to ZD1839 for variable
periods prior to irradiation on the MGH-U1 and S40b cell lines. Cells were
exposed to ZD1839 (0.01mM) for 1, 3 and 6 days prior to irradiation with
the drug being replenished every 24h. No difference in the radiosensitising
effect was detected whether drug was administered for 24h or 6 days prior
to irradiation, although overall radiosensitisation was still highly significant
(Po0.001). (XRT only¼K; ZD1839 1 day¼’; ZD1839 3 days¼m;
ZD1839 6 days¼.).
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s24.3% of cells were undergoing apoptosis compared to control
values of 5.7% (P¼0.04), while in the MGH-U1 cell line, 20.3% of
cells were undergoing apoptosis compared to control values of
5.3% (P¼0.04), Figure 6.
DISCUSSION
Manipulation of growth factor receptors such as EGFR and the
subsequent effect on downstream signalling cascades has been of
much interest in the development of novel cancer therapies (Fry,
1999). EGFR is a factor with a key regulatory role in a wide variety
of solid malignancies and EGFR signalling cascades have been
implicated in cellular processes such as proliferation, angiogenesis,
invasion and metastasis (Salomon et al, 1995). Manipulation of
this receptor in combination with standard cancer therapies such
as chemotherapy and radiotherapy might therefore offer the
potential for increased efficacy of established treatments without
significantly increasing overall cellular toxicity. The two main
modalities for manipulation of EGFR include the blockade of the
receptor with anti-EGFR monoclonal antibodies (Herbst and Shin,
2002) and inhibition of the receptor with small molecule EGFR
tyrosine kinase inhibitors such as ZD1839 (Albanell et al, 2001).
ZD1839 has been shown to have growth inhibitory effects across
a wide variety of cell types. The IC50 for ZD1839 has been reported
to be relatively cell line specific with values ranging from 0.15 to
31mM (Ciardiello et al, 2001a; Magne et al, 2002). In our study,
ZD1839 was found to have little effect on the growth characteristics
of both cell lines as a single agent when studied at the doses
previously reported to have significant growth inhibitory effects
(Ciardiello et al, 2000). This was found to be the case when cells
were exposed to the drug for 24h or up to 6 days with the drug
being replenished on a daily basis. At higher concentrations,
ZD1839 was found to have a growth-inhibitory effect with an IC50
of 98mM in the MGH-U1 cell line and 59mM in the S40b cell line.
EGFR expression was found to be higher in the radiosensitive S40b
cell line (21.5fmolmg
 1 of protein) compared to the radioresistant
MGH-U1 line (16.7fmolmg
 1 of protein), although this does not
represent particularly high expression. Previous studies demon-
strating an inverse correlation between the IC50 of ZD1839 and
EGFR expression are in agreement with our findings (Magne et al,
2002). However, other studies have suggested that the effects of







































































































Figure 4 Radiosensitising effect of exposure to increasing concentrations
of ZD1839 for 24h prior to irradiation on the MGH-U1 and S40b cell lines.
Cells were exposed to ZD1839 0.01, 1.0 and 10mM for 24h prior to
irradiation. No significant difference was demonstrated in the radio-
sensitising effect with the higher concentrations of ZD1839 compared to
ZD1839 at a concentration of 0.01mM (P¼0.8), although overall
radiosensitisation was still highly significant (Po0.001). (XRT only¼K;

































































 S40b 0.1 M
 S40b 10 M
Figure 5 Effects of exposure to ZD1839 on cell cycle kinetics. Cells
were treated with ZD1839 at concentrations of 0.1 and 10mM for 24h.
Cells were analysed 48h after exposure using PI staining and flow
cytometry. No significant difference was demonstrated in the proportion of
cells in each phase of the cell cycle following exposure to ZD1839 in either
cell line at either drug concentration.
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sand may involve a complex interaction of heterodimerisation of
ErbB-1 (EGFR) with other glycoprotein receptors in the subfamily
such as ErbB-2 or ErbB-3 (Normanno et al, 2002).
One of the mechanisms by which ionising radiation has been
shown to induce apoptosis is via activation of the stress-activated
protein kinase pathway, also known as the c-Jun N-terminal kinase
(SAPK/JNK) pathway (Verheij et al, 1996). However, ionising
radiation can also result in the activation of EGFR which, via
activation of the ras/raf mitogen-activated protein kinase (MAPK)
cascade, exerts a delicate inhibitory effect upon the SAPK/JNK
pathway and therefore can afford a degree of protection from
the proapoptotic effects of ionising radiation (Carter et al,
1998; Verheij et al, 1998). Inhibition or an imbalance of
downstream signalling cascades via an EGFR-TKI may disrupt
this inbuilt protective mechanism and increase radiation-induced
cell death.
ZD1839 was found to have a highly significant radiosensitising
effect on both the radioresistant MHG-U1 cell line and its
radiosensitive mutant clone S40b when added for 24h preirradia-
tion. Prolonged exposure to ZD1839 for 3 or 6 days with the drug
being replenished daily did not further enhance the overall
radiosensitising effect of the 24h exposure regimen. Thus, the
length of exposure to ZD1839 prior to irradiation appears to have
no significant additional radiosensitising effect than exposure for
24h preirradiation. These data would suggest that exposure to
ZD1839 shortly before irradiation is sufficient to increase overall
cell death and that prior treatment for greater than 24h adds little
to the radiosensitising effect. The concentration of ZD1839 was
also examined to assess if this would improve the established
radiosensitising effect. However, increasing the concentration of
ZD1839 to 1.0 and 10mM for 24h prior to irradiation did not
increase the overall induced cell death. This suggests that the EGFR
signalling cascade is sufficiently inhibited at concentrations of
0.01mM.
Exposure to ZD1839 for 24h had no significant effect on cell
cycle kinetics when analysed at 24 and 48h postexposure. This is
contrary to previously published data in a range of cell lines, where
exposure has resulted in an accumulation of cells in the G0/G1
phase of the cell cycle with a subsequent decrease in the S-phase
proportion (Bianco et al, 2002). However, our results are in
agreement with published data on the mesothelioma cell line
H2591, which did not display G1 arrest at concentrations of
ZD1839 up to 10mM (Janne et al, 2002). This suggests that the
radiosensitising effect of ZD1839 does not depend on cell cycle
inhibition or alteration of cell cycle kinetics to any significant
degree in the bladder cancer cell lines studied.
There was a modest induction of apoptosis with ZD1839 used as
a single agent (5–6% above background) and this was similar in
both cell lines. Treatment with radiation alone resulted in the
induction of apoptosis in both cell lines and this was significantly
more extensive for the radiosensitive S40b cell line than the parent
MGH-U1 line (17.8 and 12.5%, respectively). Combination
treatment with ZD1839 and radiation resulted in a marked
induction of apoptosis in both cell lines compared to control cells
(24.3 and 20.3% for the S40b and MGH-U1 cell lines, respectively).
The mechanism by which ZD1839 promotes apoptosis as a single
agent and in combination with ionising radiation is currently
under investigation (Huang et al, 2002). Ionising radiation
activates the SAPK/JNK pathway resulting in apoptosis and
necrotic cell death. As previously stated, ionising radiation leads
to the activation of EGFR which, via intracellular tyrosine kinase
phosphorylation, results in subtle inhibition of downstream
signalling messengers and reduced apoptosis. It has been
suggested that ZD1839 leads to an imbalance of homo- and
heterodimerisation of the ErbB family of tyrosine kinase protein
receptors resulting in an increase in the EGFR-ErbB2 and EGFR-
ErbB3 heterodimer complexes. These complexes are inactive
resulting in a decrease of EGFR downstream signalling and loss
of the EGFR inhibitory effect on the SAPK/JNK pathway resulting
in an increased apoptosis (Normanno et al, 2001). Published
studies have also proposed that ZD1839 prevents MAPK-depen-
dent serine phosphorylation of the proapoptotic regulatory protein
BAD, a member of the BH3 subfamily, resulting in it remaining in
its active form (Gilmore et al, 2002). This inhibition of
phosphorylation of serine residues also inhibits the interaction
between BAD and BCL-XL, an antiapoptotic regulatory protein of
the BH3 subfamily, resulting in BAD remaining in an active
proapoptotic form. Reports have also suggested that ZD1839
decreases the phosphorylation of Akt via the phosphatidylinositol
3-kinase pathway resulting in decreased phosphorylation of BAD
again resulting in an increase in the proportion of the active form
of this regulatory protein (Kennedy et al, 1999). A combination of
the proposed models or elements of the models may result in the
loss of the fine balance of the EGFR signalling cascade, which
protects against radiation-induced cell damage, thereby leading to
increased cell death.
The possible mechanisms for the potentiation of radiation-
induced cell death by ZD1839 remain to be established and require
further investigation. However, our study suggests that despite the
relatively high concentrations of ZD1839 needed to achieve
cytotoxicity in bladder cancer cell lines (IC50 was 98 and 59mM
in the MGH-U1 and S40b cell lines, respectively) and the lack of
any significant alteration in cell cycle kinetics, there is a definite
and pronounced radiosensitising effect in the radioresistant MGH-
U1 cell line and an even greater effect in its radiosensitive mutant
clone S40b. These results, in conjunction with those of a number of
other groups, suggest that ZD1839 has a significant effect on
potentiating radiation-induced cell death at doses higher than 2Gy
in a wide variety of cells of varying radiosensitivity. The
potentiation of cell death induced in the radioresistant and the
radiosensitive cell line is an encouraging feature as many tumours
are inherently heterogeneous in their radiosensitivity (Steel, 1997).
Radical radiotherapy is an established treatment modality for
muscle invasive bladder cancer with curative results equivalent to
radical surgery. This study demonstrates a possible role for
ZD1839 as an adjuvant to radiotherapy as a means of overcoming
radioresistance and improving outcomes in the organ sparing
treatment of invasive bladder cancer.
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Figure 6 Effects of exposure to ZD1839 for 24h on apoptosis. Cells
were exposed to ZD1839 only (0.01mM), 10Gy only or the combination
of ZD1839þ10Gy. Significant induction of apoptosis was demonstrated
with the combination of ZD1839þionising radiation (P¼0.04 for both
MGH-U1 and S40b).
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